Results 141 to 150 of about 824,117 (206)

Preparation and Activities of Macromolecule Conjugates of the CCR5 Antagonist Maraviroc

open access: yes, 2016
CCR5 antagonists are among the most advanced approaches in HIV therapy and may also be relevant to treatment of graft-versus-host disease and Staphylococcus aureus infection.
Julia Gavrilyuk (1396897)   +3 more
core   +1 more source

Evasins: Biology and Therapeutic Potential of Broad‐Spectrum Chemokine Inhibitors

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
ABSTRACT Ticks are haematophagous parasites that rely on uninterrupted bloodmeals for survival and need an effective strategy to suppress the host inflammatory response. Leukocyte recruitment is a chemokine‐mediated hallmark of inflammation, which ticks counteract via anti‐chemokine proteins in their saliva named evasins.
Emilia L. Bialek   +3 more
wiley   +1 more source

Nonpathogenic SIV Infection in Sooty Mangabeys Is Characterized by a Lack of Activation and Expansion of Monocytes

open access: yesJournal of Medical Primatology, Volume 55, Issue 5, October 2026.
ABSTRACT Introduction Natural hosts of simian immunodeficiency virus (SIV), including sooty mangabeys (SMs), maintain high viremia without progressing to AIDS and AIDS‐associated histopathogenesis. The mechanisms underlying this protection and lack of pathogenesis remain incompletely understood, particularly in relation to monocyte/macrophage ...
Caroline Soulas   +7 more
wiley   +1 more source

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome

open access: yesFrontiers in Pharmacology
Introduction: The acute respiratory distress syndrome (ARDS), secondary to viral pneumonitis, is one of the main causes of high mortality in patients with COVID-19 (novel coronavirus disease 2019)—ongoing SARS-CoV-2 infection— reached more than 0.7 ...
Aleksandr S. Chernov   +11 more
doaj   +1 more source

From HTS to Market: the Discovery and Development of Maraviroc, a CCR5 Antagonist for the Treatment of HIV

open access: yes, 2010
AIDS has claimed the lives of over 25 million people, driving the continuing desire to identify new treatments for this devastating disease. Maraviroc, the first CC Chemokine Receptor 5 (CCR5) antagonist to be licensed as a treatment for HIV, works by ...
Chris Barber, David Pryde
core   +1 more source

Analyse par suivi de particule unique à la surface de lymphocytes vivants de l'organisation dynamique des récepteurs CD4 et CCR5 impliqués dans l'infection par le VIH [PDF]

open access: yes, 2012
L'infection de lymphocytes T CD4+ par le virus de l'immunodéficience humaine (VIH) débute par l'interaction séquentielle de la protéine d'enveloppe du virus gp120 avec le récepteur primaire CD4 puis avec un corécepteur, CCR5 dans la majorité des cas de ...
Mascalchi, Patrice
core  

A CCR5 antagonist enhances the radiosensitivity of hepatocarcinoma in a mouse model. [PDF]

open access: yesJ Radiat Res
Chen J   +9 more
europepmc   +1 more source

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.

open access: yesProceedings of the National Academy of Sciences of the United States of America, 1999
M. Baba   +11 more
semanticscholar   +1 more source

CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.

open access: yes, 1999
CCR5 was first characterized as a receptor for MIP-1alpha, MIP-1beta, and RANTES, and was rapidly shown to be the main coreceptor for M-tropic human immunodeficiency virus (HIV)-1 strains and simian immunodeficiency virus (SIV).
Doranz, Benjamin J.   +8 more
core  

Home - About - Disclaimer - Privacy